{"id":40116,"date":"2025-08-26T15:32:52","date_gmt":"2025-08-26T07:32:52","guid":{"rendered":"https:\/\/flcube.com\/?p=40116"},"modified":"2025-08-26T15:32:52","modified_gmt":"2025-08-26T07:32:52","slug":"bioarctic-novartis-announce-braintransporter%e2%80%91enabled-neurodegeneration-collaboration-up-to-772-m-potential-pay%e2%80%91out","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40116","title":{"rendered":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out"},"content":{"rendered":"\n<p>Swedish biopharma <strong>BioArctic AB<\/strong> (publ) (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIOA-B:STO\">STO: BIOA-B<\/a>) has entered into an <strong>option, collaboration, and license agreement<\/strong> with <strong>Novartis Pharma AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/NVS:NYSE\">NYSE: NVS<\/a>) to merge BioArctic\u2019s proprietary <strong>BrainTransporter<\/strong> technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).<\/p>\n\n\n\n<p><strong>How BrainTransporter Works<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active transport<\/strong> of biologics across the BBB using TfR\u2011mediated transcytosis.<\/li>\n\n\n\n<li><strong>Broader brain distribution<\/strong> \u2192 higher therapeutic concentrations in key disease regions.<\/li>\n\n\n\n<li><strong>Improved safety<\/strong> and dosing convenience, as lower systemic exposure is required.<\/li>\n<\/ul>\n\n\n\n<p><strong>Financial Structure<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Amount<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td>Upfront cash<\/td><td><strong>$30\u202fM<\/strong><\/td><td>Paid to BioArctic upon signing.<\/td><\/tr><tr><td>Option to license<\/td><td>\u2013<\/td><td>Novartis will evaluate data and decide whether to exercise.<\/td><\/tr><tr><td>Upside potential<\/td><td><strong>$772\u202fM<\/strong><\/td><td>If Novartis licenses a drug candidate.<\/td><\/tr><tr><td>Royalty tier<\/td><td><strong>Mid\u2011single digit<\/strong><\/td><td>Applied to global product sales if marketed.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Strategic Impact<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011class<\/strong> antibody therapy that can reach therapeutic concentrations in the CNS.<\/li>\n\n\n\n<li><strong>Neurodegeneration focus<\/strong> aligns with growing market demand for Alzheimer\u2019s, Parkinson\u2019s, and other CNS disorders.<\/li>\n\n\n\n<li><strong>Synergy<\/strong>: BioArctic brings a proven BBB delivery platform; Novartis supplies a high\u2011profile antibody pipeline and global commercialization expertise.<\/li>\n<\/ul>\n\n\n\n<p><strong>Next Steps<\/strong><\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Initial research collaboration<\/strong> \u2013 BioArctic and Novartis will generate pre\u2011clinical data using the BrainTransporter\u2011antibody combo.<\/li>\n\n\n\n<li><strong>Evaluation<\/strong> \u2013 Novartis will assess the data and decide whether to exercise the license option.<\/li>\n\n\n\n<li><strong>Potential rollout<\/strong> \u2013 If the option is exercised, the partnership will move into advanced pre\u2011clinical and early\u2011clinical development, with a view to regulatory submission in the next 3\u20135 years.<\/li>\n<\/ol>\n\n\n\n<p><strong>Takeaway<\/strong><br>The BioArctic\u2011Novartis collaboration represents a significant leap forward in CNS drug delivery, combining an innovative BBB\u2011penetration platform with a potent neurodegeneration antibody. With an upfront $30\u202fM payment and a potential $772\u202fM upside, the deal positions both companies at the forefront of a rapidly expanding neurodegenerative therapeutics market.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license&#8230;<\/p>\n","protected":false},"author":1,"featured_media":40119,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[1],"tags":[1816,140,865,1817],"class_list":["post-40116","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-bioarctic","tag-novartis","tag-nyse-nvs","tag-sto-bioa-b"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40116\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out\" \/>\n<meta property=\"og:description\" content=\"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40116\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T07:32:52+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out\",\"datePublished\":\"2025-08-26T07:32:52+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116\"},\"wordCount\":322,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2614.webp\",\"keywords\":[\"BioArctic\",\"Novartis\",\"NYSE: NVS\",\"STO: BIOA-B\"],\"articleSection\":[\"Others\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40116#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40116\",\"name\":\"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2614.webp\",\"datePublished\":\"2025-08-26T07:32:52+00:00\",\"description\":\"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40116\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2614.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2614.webp\",\"width\":1080,\"height\":608,\"caption\":\"BioArctic & Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40116#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out - Insight, China&#039;s Pharmaceutical Industry","description":"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40116","og_locale":"en_US","og_type":"article","og_title":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out","og_description":"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).","og_url":"https:\/\/flcube.com\/?p=40116","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T07:32:52+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40116#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40116"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out","datePublished":"2025-08-26T07:32:52+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40116"},"wordCount":322,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40116#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","keywords":["BioArctic","Novartis","NYSE: NVS","STO: BIOA-B"],"articleSection":["Others"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40116#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40116","url":"https:\/\/flcube.com\/?p=40116","name":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40116#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40116#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","datePublished":"2025-08-26T07:32:52+00:00","description":"Swedish biopharma BioArctic AB (publ) (STO: BIOA-B) has entered into an option, collaboration, and license agreement with Novartis Pharma AG (NYSE: NVS) to merge BioArctic\u2019s proprietary BrainTransporter technology with Novartis\u2019 novel antibody against an undisclosed neurodegenerative target. The partnership could unlock the first antibody\u2011based therapy that delivers drugs efficiently across the blood\u2011brain barrier (BBB) via the transferrin receptor (TfR).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40116#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40116"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40116#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","width":1080,"height":608,"caption":"BioArctic & Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40116#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BioArctic &amp; Novartis Announce BrainTransporter\u2011Enabled Neurodegeneration Collaboration \u2013 Up to $772\u202fM Potential Pay\u2011Out"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2614.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40116","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40116"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40116\/revisions"}],"predecessor-version":[{"id":40120,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40116\/revisions\/40120"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40119"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}